Catumaxomab
- Generic Name
- Catumaxomab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 509077-98-9
- Unique Ingredient Identifier
- M2HPV837HO
- Background
Catumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites . Its market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency. Catumaxumab was approved for market in Canada in May 2012 for the same condition . It is currently available under the brand name Removab.
- Indication
For use in the management of malignant ascites tumours via intraperitoneal infusion where standard therapy is not available or feasible .
- Associated Conditions
- Ascites, Malignant
- Associated Therapies
- Palliative Treatment
Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Lindis Biotech GmbH
- Target Recruit Count
- 30
- Registration Number
- NCT04819399
- Locations
- 🇩🇪
Urologie Planegg, München, Germany
Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- LintonPharm Co.,Ltd.
- Target Recruit Count
- 161
- Registration Number
- NCT04799847
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Peking University Third Hospital, Beijing, China
Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis
- Conditions
- Interventions
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- LintonPharm Co.,Ltd.
- Target Recruit Count
- 282
- Registration Number
- NCT04222114
- Locations
- 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳China Medical University Hospital, Taichung, Taiwan
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer
- First Posted Date
- 2013-03-21
- Last Posted Date
- 2015-02-18
- Lead Sponsor
- JSehouli
- Target Recruit Count
- 2
- Registration Number
- NCT01815528
- Locations
- 🇩🇪
Charité Campus Virchow-Klinikum, Berlin, Germany
A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients
- First Posted Date
- 2011-03-22
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Neovii Biotech
- Target Recruit Count
- 16
- Registration Number
- NCT01320020
- Locations
- 🇦🇹
Prof. Christian Dittrich, Wien, Austria
🇪🇸Dr. Josep Tabernero, Barcelona, Spain
🇩🇰Dr. Morten Soerensen, Copenhagen, Denmark
Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission
- First Posted Date
- 2010-11-23
- Last Posted Date
- 2016-08-11
- Target Recruit Count
- 39
- Registration Number
- NCT01246440
- Locations
- 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Madrdi, Spain
🇪🇸Hosptial Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
🇪🇸Hospital Universitario Fundación Alcorcon, Alcorcon, Madrid, Spain
Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites
- Conditions
- Interventions
- First Posted Date
- 2010-02-09
- Last Posted Date
- 2012-10-03
- Lead Sponsor
- Neovii Biotech
- Target Recruit Count
- 8
- Registration Number
- NCT01065246
- Locations
- 🇩🇪
Charité Campus Virchow Clinic, Berlin, Germany
CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers
- Conditions
- Interventions
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2012-10-03
- Lead Sponsor
- Neovii Biotech
- Target Recruit Count
- 230
- Registration Number
- NCT00822809
- Locations
- 🇩🇪
Study site, Several, Germany
🇪🇸Study Site, Several, Spain
Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2012-10-03
- Lead Sponsor
- Neovii Biotech
- Target Recruit Count
- 41
- Registration Number
- NCT00563836
- Locations
- 🇩🇪
Klinikum Charité, Berlin, Germany
Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection
- First Posted Date
- 2007-04-24
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Neovii Biotech
- Target Recruit Count
- 70
- Registration Number
- NCT00464893
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.